Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05203835 · ClinicalTrials.gov registry record · Phase 2
Trial of Acebilustat for the Treatment of Upper Arm Lymphedema
A Phase 2 study of Lymphedema of Upper Arm, sponsored by Stanford University.
- Active
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05203835: Active Phase 2 study of Lymphedema of Upper Arm, sponsored by Stanford University.
NCT05203835 is a Phase 2 study of Lymphedema of Upper Arm that is active but no longer recruiting, run by Stanford University. The registered enrollment target is 40 participants, below the 151-participant average among 3 other Lymphedema of Upper Arm trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05203835, a Phase 2 study of Lymphedema of Upper Arm, is active but no longer recruiting, sponsored by Stanford University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to investigate the response of unilateral upper extremity (arm) lymphedema, during pharmacologic treatment of lymphedema with oral placebo and oral acebilustat. Participants will receive "study drug" (Acebilustat or placebo), for 9 months. For 3 of these months, the participant will receive placebo; for 6 of these months, the participant will receive active ingredient, acebilustat. The study is blinded which means that the participant will not be told which study pill they are taking.
Primary Outcome
Cutaneous thickness will be measured by skin calipers at three designated locations in the affected upper extremity.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Acebilustat
Study Locations (1)
California
- Stanford University - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-07-27 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 2 |
What the registry record for NCT05203835 still lists
NCT05203835 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 151-participant average among 3 other Lymphedema of Upper Arm trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Lymphedema of Upper Arm appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05203835 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05203835 about?
NCT05203835 is a clinical study titled "Trial of Acebilustat for the Treatment of Upper Arm Lymphedema". This study is designed to investigate the response of unilateral upper extremity (arm) lymphedema, during pharmacologic treatment of lymphedema with oral placebo and oral acebilustat. Participants will receive "study drug" (Acebilustat or placebo), for 9 months. For 3 of these months, the participan...
What is the current status of trial NCT05203835?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2022-07-27. Estimated completion is 2026-03-31.
What conditions does trial NCT05203835 study?
This clinical trial studies the following conditions: Lymphedema of Upper Arm.
What interventions are being tested in trial NCT05203835?
The interventions under investigation include: Placebo (DRUG), Acebilustat (DRUG).
Who is sponsoring clinical trial NCT05203835?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05203835 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphedema of Upper Arm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Screening For BCRL In Targeted Therapy For Breast Cancer
ACTIVE NOT RECRUITING
-
Ipsilateral Peripheral Intravenous Access Procedures (The iPIVAP Study)
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI